Filing Flows

Filing Flows › Comparisons › BFRG vs SXTP

BullFrog AI Holdings vs 60 Degrees Pharmaceuticals: BFRG and SXTP compared

BullFrog AI Holdings is the larger company: $215K of revenue in its latest quarter (Q2 2026) against $208K for 60 Degrees Pharmaceuticals (Q2 2026). BullFrog AI Holdings is growing faster (+548% against +106% a year earlier).

BullFrog AI Holdings vs 60 Degrees Pharmaceuticals, latest quarterBullFrog AI Holdings vs 60 Degrees Pharmaceuticals, latest quarterBullFrog AI Holdings (BFRG)60 Degrees Pharmaceuticals (SXTP)Revenue$215K$208KRevenue growth, Y/Y+548%+106%Operating margin-658.8%n/m

Where the money goes: BFRG and SXTP

BullFrog AI Holdings (BFRG) · Q2 2026

BullFrog AI Holdings, Q2 2026: revenue $215K (+548% year over year), operating margin -658.8%, net loss $1.4M, operating cash flow −$1.5M. The chart follows the revenue to costs, profit and cash.

60 Degrees Pharmaceuticals (SXTP) · Q2 2026

60 Degrees Pharmaceuticals, Q2 2026: revenue $208K (+106% year over year), net loss $2.3M, operating cash flow −$2.2M. The chart follows the revenue to costs, profit and cash.

BullFrog AI Holdings (BFRG)60 Degrees Pharmaceuticals (SXTP)
Latest quarterQ2 2026Q2 2026
Revenue$215K$208K
Revenue growth, Y/Y+548%+106%
Operating margin-658.8%n/m
Net earnings−$1.4M−$2.3M
Net margin-636.8%—
Operating cash flow−$1.5M−$2.2M

Questions

Which is bigger, BullFrog AI Holdings or 60 Degrees Pharmaceuticals?

BullFrog AI Holdings is the larger company: $215K of revenue in its latest quarter (Q2 2026) against $208K for 60 Degrees Pharmaceuticals (Q2 2026).

Is BullFrog AI Holdings or 60 Degrees Pharmaceuticals growing faster?

BullFrog AI Holdings is growing faster (+548% against +106% a year earlier).

More: BullFrog AI Holdings earnings · how BullFrog AI Holdings makes money · 60 Degrees Pharmaceuticals earnings · how 60 Degrees Pharmaceuticals makes money

From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.